Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2022 | $6.00 | Buy | Maxim Group |
LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET. Shareholder Update Call Details:Date: April 21, 2026Time: 4:30 P.M. ETLive Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)Webcast: Events and Presentations About NEXGEL, Inc.NEXGEL is a leading provider of healthcare, beauty, and over-th
LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET. While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a diffe
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 15, 2026, at 4:30 P.M. ET. While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a diffe
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
10-K - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr
LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company's previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC. In connection with the investment, NexGelRx has appointed Mr. Gruntfest to serve as a board observer and advisor, bringing deep experience in reimbursement strategy, patient access, and healthca
LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:SSTK), Mr. Ciardiello has a proven track record of financial leadership, strategic execution, and corporate governance in high-growth, publicly traded companies. "Steve's extensive experience, financial leader
LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET. Shareholder Update Call Details:Date: April 21, 2026Time: 4:30 P.M. ETLive Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)Webcast: Events and Presentations About NEXGEL, Inc.NEXGEL is a leading provider of healthcare, beauty, and over-th
LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET. While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a diffe
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 15, 2026, at 4:30 P.M. ET. While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a diffe